Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: Detection of the T315I mutation in bone Marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood

Molecular Diagnosis and Therapy

Volumn 16, Issue 3, 2012, Pages 163-166

  Razga, Filip ^a   Jurcek, Tomas ^a   Jeziskova, Ivana ^a   Zackova, Daniela ^a   Dvorakova, Dana ^a,b   Borsky, Marek ^a   Mayer, Jiri ^a,b   Racil, Zdenek ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Bcr abl tyrosine kinase inhibitors; Chronic myeloid leukaemia; Imatinib; Leukaemia; Protein tyrosine kinase inhibitors; Protein tyrosine kinase targets

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 KINASE; CD34 ANTIGEN; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD CELL; BLOOD TOXICITY; BONE MARROW CELL; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CASE REPORT; CELL CLONE; CELL EXPANSION; CELL MATURATION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MUTATIONAL ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SEQUENCE ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84861663006     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11632420-000000000-00000     Document Type: Article

References (16)

1. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract no. 1126]. Blood 2009; 114 (22): Abstract no. 1126
2. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109 (6): 2303-9
3. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110 (10): 3540-6
4. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8 (11): 1018-1029
5. Branford S. Chronic myeloid leukemia: Molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007; 376-83
6. Soverini S, Colarossi S, Gnani A, et al., GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12 (24): 7374-9
7. Chomel JC, Sorel N, Bonnet ML, et al. Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitorresistant chronic myeloid leukemia. Leuk Lymphoma 2010; 51 (11): 2103-2111
8. Minami Y, Kajiguchi T, Abe A, et al. Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment. Int J Hematol 2010; 92 (4): 664-6
9. Poláková KM, PolívkováV, RulcováJ, et al. Constant BCR-ABL transcript level '0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol 2010; 38 (1): 20-26
10. Gabert J, Beillard E, Van Der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: A Europe Against Cancer program. Leukemia 2003; 17 (12): 2318-2357
11. Poláková KM, LopotováT, KlamováH, et al. High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008; 32 (8): 1236-1243
12. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108 (1): 28-37
13. Khorashad JS, De Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008; 26 (29): 4806-4813
14. Soverini S, Martinelli G, Amabile M, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 2004; 50 (7): 1205-1213
15. Khorashad JS, Thelwell N, Milojkovic D, et al. Anew rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia. J Clin Pathol 2008; 61 (7): 863-5
16. Pelz-Ackermann O, Cross M, Pfeifer H, et al. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia 2008; 22 (12): 2288-2291